To print: Select File and then Print from your browser's menu

Title: Docetaxel Improves Survival in Women With Metastatic Breast Cancer: Presented at SABCS

"Docetaxel Improves Survival in Women With Metastatic Breast Cancer: Presented at SABCS"

By Charlene Laino SAN ANTONIO, TX -- December 4, 2003 -- For women with metastatic breast cancer who have failed prior chemotherapy, docetaxel is associated with a significant improvement in overall survival and time to disease progression, when compared with paclitaxel, a Phase III randomised trial shows. Despite an increase in certain toxicities, there was no difference in quality-of-life scores between the 2 groups, said Stephen E. Jones, MD, Medical Director of U.S. Oncology Research and Director of Breast Cancer Research, Baylor-Sammons Cancer Center, Dallas, Texas, United States. Dr. Jones presented the findings here on December 3rd at the 26th annual San Antonio Breast Cancer Symposium. The trial -- the first to directly compare docetaxel and paclitaxel -- enrolled 449 women with metastatic breast cancer, who were randomised to receive either 100 mg/m2 of docetaxel as a 1-hour infusion or 175 mg/m2 of paclitaxel as a 3-hour infusion, every 3 weeks. The drugs were continued until progression of disease, unmanageable toxicity, or until the patient opted to terminate treatment. In the intent-to-treat population, median survival was 15.4 months in the arm receiving docetaxel, compared with 12.7 months in the group receiving paclitaxel. This finding translated to 41% relative improvement in overall survival attributable to docetaxel, which was significant at the P = .03 level, Dr. Jones reported. Also, time to disease progression was 5.7 months for women taking docetaxel, compared with 3.6 months for those on paclitaxel. This translated to a 62% improvement in time to disease progression (P < .0001). Overall response rates were 32% in the docetaxel arm versus 25.0% in the paclitaxel arm (P = .10), the study showed. There were more haematological toxicities with docetaxel therapy, Dr. Jones said, mainly Grade 3/4 neutropenia. Fifteen percent of the patients in the docetaxel arm suffered febrile neutropenia versus 2% of patients on paclitaxel. Quality-of-life scores, however, as assessed by a modified Functional Assessment of Cancer Therapy questionnaire, were not significantly different between the 2 arms after 4 cycles of treatment, Dr. Jones reported. Aventis Pharmaceuticals sponsored this trial. [Study Title: Randomized Trial Comparing Docetaxel and Paclitaxel in Patients with Metastatic Breast Cancer. Abstract 10]

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.